Refine by
Dosing System Articles & Analysis: Older
32 news found
This accuracy reduces the risk of over or under-dosing and improves therapeutic outcomes. The advantages of this drug delivery system extend beyond patient convenience and precise dosing, as the technology also enhances the bioavailability of drugs. ...
By combining the benefits of sustained release with the ease of injection, CD Formulation has developed a solution that addresses the limitations associated with frequent dosing. These new technologies, including drug half-life extension technologies, injection site drug reservoir technologies, and drug physicochemical enhancement technologies, offer new possibilities in the ...
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. ...
As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabetes Management System, the Amgen Neulasta On Body Injector, and the Ferring Pharmaceutical LutrePulse System. ...
The cream will be packaged in a metered-dose, airless pump system, designed to deliver a measured dose of API consistently per actuation and to protect the APIs from known sources of degradation, namely light and oxygen. ...
The first potential device made on the ApiJect Platform is the Prefilled ApiJect Injector, a single-dose prefilled injector designed to efficiently deliver a 0.5mL dose into a patient with a simple squeeze of the BFS container by the healthcare professional. ...
“Now with data from up to five patients, we have observed a strong safety and tolerability profile, as well as a reduction in the harmful accumulation of cystine crystals in cells across multiple tissues. “All five patients dosed to date remain off oral cysteamine. We believe the results to date for this investigational gene therapy show its potential to stabilize or ...
Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vialsto market a generic equivalent of Brovana®Inhalation Solution, 15 mcg/2 ml of Sunovion Pharmaceuticals Inc. (Sunovion). ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ...
Enesi Pharma is pleased to acknowledge Lynette Eyb’s excellent article ‘A Total Meltdown’ in Medical Device Developments’ where the potential of Enesi’s proprietary ImplaVax® formulation and delivery technologies are discussed. The Article ‘A Total Meltdown‘ highlights how next generation vaccination technologies such as ImplaVax® needle-free, ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative biotechnology company developing ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), which this year is free to attend. ...
Enesi Pharma recently hosted a crew from Asahi TV, one of Japan’s leading TV channels, at its Oxford, UK facility to talk about the potential of its ImplaVax® solid dose needle-free vaccination technology. The conversation coincided with the approval of the Pfizer/BioNTech COVID-19 vaccine Comirnaty® in Japan and potential dose-wasting issues linked to the type of syringe used in ...
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable ...
The OneDose ReadyfusOR Gen2 is the second generation of the Company’s original OneDose ReadyfusOR infusion system and was developed to further improve patient convenience. The new OneDose ReadyfusOR Gen2 comes in a smaller size and with a significant weight reduction compared to the original product. The CE Mark approval demonstrates that BioQ’s OneDose ReadyfusOR ...
“Digital SPECT MPI has been shown to add significant value in terms of patient exam image quality, radiation dose reduction, procedure speed, and new advanced applications,” explains Jim Haisler, vice president of global operations for Spectrum Dynamics Medical. ...
Meissa’s COVID-19 vaccine candidate offers significant potential advantages for global deployment, including needle-free intranasal administration, a single adjuvant-free dose to induce systemic and mucosal immunity, and a straightforward, economical, and scalable manufacturing process capable of supplying global demands. ...
Objective We explored whether the use of a pharmaceutic strategy targeting efficacious systemic dose concentrations, but with diminished peak serum concentrations and/or total drug exposure would mitigate hepatotoxicity. Twice-daily dosing of an extended-release formulation of onapristone was developed and clinically evaluated in light of renewed ...